<DOC>
	<DOCNO>NCT00718380</DOCNO>
	<brief_summary>The objective study evaluate pharmacokinetics , safety tolerability ABT-869 Japanese patient solid tumor Recommended Phase Two Dose determine previous M04-710 study .</brief_summary>
	<brief_title>A Phase 1 Study ABT-869 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Subjects age 20 75 year ECOG PS 02 screening . Subject must solid tumor refractory standard therapy standard effective therapy exist . The subject must adequate bone marrow , renal hepatic function . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation six month follow completion therapy . The subject must voluntarily sign date inform consent . Exclusion Criteria The subject currently exhibit symptomatic intervention indicate CNS metastasis . The subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , biologic investigational therapy within 4 week enrollment fully recover toxicity result past treatment ( ) affect assessment study enrollment . The subject follow condition screen assessment . 1. proteinuria CTC grade &gt; 1 measure urinalysis 24 hour urine collection 2. diastolic blood pressure ( BP ) &gt; 95 mmHg ; systolic blood pressure ( BP ) &gt; 150 mmHg 3. history currently exhibit clinically significant cancer relate event bleed 4 . LV Ejection Fraction &lt; 50 % 5. receive cumulative dose Anthracycline &gt; 360 mg/m2 treatment cancer 6. receive therapeutic anticoagulation therapy 7. fracture except chronic bone lesion due bone metastases The subject exhibit evidence clinically significant uncontrolled condition ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>